FEATURED

Valar Labs: Reimagining Cancer Treatment Decisions with Artificial Intelligence

March 20, 2022

News & Resources

Latest News

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology
July 2025

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology
July 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire
June 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire
June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology
June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology
June 2025